Milind Desai, MD, MBA

Andrew Wang, MD; James Januzzi, MD; Michelle M. Kittleson, MD, PhD; and Milind Desai, MD, MBA, share a look into the future of oHCM treatment.

Michelle M. Kittleson, MD, PhD, comments on remaining unanswered questions regarding CMIs in treatment of oHCM, highlighting disease modification.

Expert cardiologists share approaches to implementing mavacamten and aficamten in the clinical treatment of oHCM.

Andrew Wang, MD, and Anjali Owens, MD, review the clinical trials of aficamten, a CMI used for treating patients with oHCM.

Milind Desai, MD, MBA, and Michelle M. Kittleson, MD, PhD, review the clinical trial data of mavacamten, the first FDA-approved cardiac myosin inhibitor for the treatment of oHCM.

Andrew Wang, MD, discusses the use of cardiac myosin inhibitors (CMIs) as a new, less invasive option for treating oHCM.

Andrew Wang, MD, comments on the treatment algorithm for symptomatic oHCM, highlighting treatment guidelines, and James Januzzi, MD, reviews treatment selection for oHCM through the lens of the patient’s quality of life.

Expert cardiologists discuss treating patients with symptomatic vs asymptomatic oHCM.

Milind Desai, MD, MBA, leads a discussion on the importance of accurate imaging in oHCM and aortic stenosis, highlighting the echocardiogram and doppler tests.

Milind Desai, MD, MBA, comments on risk stratification for sudden cardiac death (SCD) in oHCM.

Cardiology experts discuss the importance of an accurate and prompt diagnosis of oHCM, as well as effectively educating the patient about the condition.

Michelle M. Kittleson, MD, PhD, and James Januzzi, MD, review signs that point to oHCM, highlighting family history and details on the diagnostic evaluation.

Andrew Wang, MD, outlines the epidemiology of obstructive hypertrophic cardiomyopathy (oHCM), and Milind Desai, MD, MBA, reviews the etiology of the condition.